Cargando…

Erlotinib-Cisplatin Combination Inhibits Growth and Angiogenesis through c-MYC and HIF-1α in EGFR-Mutated Lung Cancer In Vitro and In Vivo

Combination treatment for non–small cell lung cancer (NSCLC) is becoming more popular due to the anticipation that it may be more effective than single drug treatment. In addition, there are efforts to genetically screen patients for specific mutations in light of attempting to administer specific a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Jasmine G., Wu, Reen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351293/ https://www.ncbi.nlm.nih.gov/pubmed/25748238 http://dx.doi.org/10.1016/j.neo.2014.12.008

Ejemplares similares

Combination Erlotinib-Cisplatin and Atg3-Mediated Autophagy in Erlotinib Resistant Lung Cancer
por: Lee, Jasmine G., et al.
Publicado: (2012)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Combination of Huanglian Jiedu Decoction and erlotinib delays growth and improves sensitivity of EGFR-mutated NSCLC cells in vitro and in vivo via STAT3/Bcl-2 signaling
por: Zhou, Xiaowen, et al.
Publicado: (2021)

Safranal Inhibits Angiogenesis via Targeting HIF-1α/VEGF Machinery: In Vitro and Ex Vivo Insights
por: Abdalla, Ali, et al.
Publicado: (2022)

Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status
por: Lee, Youngjoo, et al.
Publicado: (2017)

Wogonin inhibits multiple myeloma-stimulated angiogenesis via c-Myc/VHL/HIF-1α signaling axis
por: Fu, Rong, et al.
Publicado: (2015)

Houshiheisan promotes angiogenesis via HIF-1α/VEGF and SDF-1/CXCR4 pathways: in vivo and in vitro
por: Xiang, Yangyang, et al.
Publicado: (2019)

The Effects of Combination of Coix Seed Extract and Cisplatin on TAM and Expression of HIF-1α in Vivo in Lewis Lung Carcinoma
por: DUAN, Guo Chen
Publicado: (2018)

EGFR in enterocytes & endothelium and HIF1α in enterocytes are dispensable for massive small bowel resection induced angiogenesis
por: Onufer, Emily J., et al.
Publicado: (2020)

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
por: Nishio, Kazuto, et al.
Publicado: (2021)

Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

HIF-1α and HIF-2α induced angiogenesis in gastrointestinal vascular malformation and reversed by thalidomide
por: Feng, Nan, et al.
Publicado: (2016)

Combination Therapy with PIK3R3-siRNA and EGFR-TKI Erlotinib Synergistically Suppresses Glioblastoma Cell Growth In Vitro
por: Amini, Razieh, et al.
Publicado: (2021)

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
por: Masuda, Chinami, et al.
Publicado: (2017)

Excellent response to erlotinib in breast carcinoma with rare EGFR mutation—a case report
por: Singh, Gunjesh Kumar, et al.
Publicado: (2020)

Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy
por: Seki, Nobuhiko, et al.
Publicado: (2019)

Apigenin Combined With Gefitinib Blocks Autophagy Flux and Induces Apoptotic Cell Death Through Inhibition of HIF-1α, c-Myc, p-EGFR, and Glucose Metabolism in EGFR L858R+T790M-Mutated H1975 Cells
por: Chen, ZiSheng, et al.
Publicado: (2019)

The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells
por: Al-Keilani, Maha S, et al.
Publicado: (2018)

Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib
por: Agbarya, Abed, et al.
Publicado: (2014)

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase
por: Dong, Jiang-Kai, et al.
Publicado: (2018)

Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment
por: Jakobsen, Jan Nyrop, et al.
Publicado: (2018)

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation
por: Nakade, Junya, et al.
Publicado: (2014)

Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
por: He, Qihua, et al.
Publicado: (2021)

Effect of erlotinib combined with cisplatin on IL-6 and IL-12 in mice with Lewis lung cancer
por: Zhang, Xu, et al.
Publicado: (2020)

NADPH Oxidase 4 Mediates Insulin-Stimulated HIF-1α and VEGF Expression, and Angiogenesis In Vitro
por: Meng, Dan, et al.
Publicado: (2012)

HIF-1α RNAi Combined with Asparagus Polysaccharide Exerts an Antiangiogenesis Effect on Hepatocellular Carcinoma In Vitro and In Vivo
por: Zhu, Tingting, et al.
Publicado: (2021)

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
por: Nakagawa, Kazuhiko, et al.
Publicado: (2022)

Dual Targeting Oncoproteins MYC and HIF1α Regresses Tumor Growth of Lung Cancer and Lymphoma
por: Huang, Xiaohu, et al.
Publicado: (2021)

The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor
por: Grépin, Renaud, et al.
Publicado: (2020)

Vhl deletion in renal epithelia causes HIF-1α-dependent, HIF-2α-independent angiogenesis and constitutive diuresis
por: Schönenberger, Désirée, et al.
Publicado: (2016)

COMMD3 Expression Affects Angiogenesis through the HIF1α/VEGF/NF-κB Signaling Pathway in Hepatocellular Carcinoma In Vitro and In Vivo
por: Zhu, Tingting, et al.
Publicado: (2022)

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
por: Pao, William, et al.
Publicado: (2005)

Predictive factors in patients with EGFR mutation-negative non-small cell lung cancer treated with erlotinib
por: ISHII, HIDENOBU, et al.
Publicado: (2014)

Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
por: Ulivi, Paola, et al.
Publicado: (2014)

A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation
por: Niwa, Hideyuki, et al.
Publicado: (2018)

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
por: Zheng, Lin-Peng, et al.
Publicado: (2018)

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum
por: Dong, Jiang-Kai, et al.
Publicado: (2021)

ABL kinases regulate the stabilization of HIF-1α and MYC through CPSF1
por: Mayro, Benjamin, et al.
Publicado: (2023)

MYC overrides HIF-1α to regulate proliferating primary cell metabolism in hypoxia
por: Copeland, Courtney A, et al.
Publicado: (2023)

HIF-1α Overexpression Induces Angiogenesis in Mesenchymal Stem Cells
por: Razban, Vahid, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_8gd1c69nf3224of7sb1c37unkt